Several nutrition and medical groups in the UK have expressed their disappointment and outrage at the Food Standard's Agency's (FSA's) refusal to act on food additives. A recent report has shown that several additives have a significant impact on ADHD in children - in fact, Professor Jim Stevenson, who carried out the research, stated that additives pose a threat to children's psychological health. The FSA Board Meeting decided to pass the buck on to the European Food Safety Authority.

 

According to the FSA, the evidence so far is not compelling enough to justify a ban. However, FSA chairman Dame Deirdre Hutton, said "I think there is a general astonishment that industry has not responded more quickly to consumer demand in terms of taking colors out of their food."

 

The FSA also decided to slightly widen the range of its advice to parents of children with ADHD (Attention Deficit Hyperactivity Disorder), but not for parents of all children. The recent study showed that food additives have an impact in attention and hyperactivity in most children, not just susceptible ones.

Some action is being taken by several retailers, who are taking additives out of their own-label products. However, nothing has been done so far regarding school meals, takeaways (takeouts), restaurants and medications for children.

Richard Watts, coordinator of Sustain's Children's Food Campaign said: "Professor Stevenson, who undertook the study on additives, told the FSA that there was the evidence necessary to ban these additives because they do pose a threat to health. Parents will be furious that the FSA has chickened out of taking this vital step to protect their children. It is simply not good enough to give consumers a bit more help to avoid these unnecessary additives. Consumers are clear they don't want to have to spend ages scanning labels to see if a product will threaten the health of their child. And people do not see the label on around half the food and drink they consume. A ban on these additives is the only appropriate step." 

 

A promising investigational HIV vaccine Phase II clinical trial has been stopped after it was determined by a panel to be ineffective. The vaccine, which had been ten years in the making, did not prevent volunteers who were at high risk for acquiring HIV infection, from becoming infected.

The trial was co-sponsored by Merck & Co., Inc., and the HIV Vaccine Trials Network, which is funded by the NIAID (National Institute of Allergy and Infectious Diseases).

参考翻译（suggested translation）

此项研究由MERCK公司和HIV疫苗试验网（由NIAID投资）联合发起。

STEP, the name of the trial, included 3,000 healthy volunteers from a variety of backgrounds, aged 18-45. According to the Merck, from one placebo group of 762 volunteers 21 became infected with HIV, while from another group of 741 who received the experimental drug 24 became infected with HIV.

 

这项研究的名字叫做STEP，包括了3000名不同背景，年龄在18-45岁的志愿者。MERCK称，使用安慰剂组的762人中21人感染了HIV，而使用试验药物的一组，741人中有24人被感染。

The STEP Independent Data Safety Monitoring Board determined that the human trial was doomed.

 

STEP独立安全监控资料确定人体试验失败。

The vaccine consisted of a common cold virus which had copies of three HIV genes. The intention was that when volunteers were exposed to the genes an immune response would be triggered which would protect them from HIV infection. As the vaccine appeared to be able to turn on the immune system, many people were optimistic that it would lead to something great. However, the vaccine failed to prevent infection, and also failed to reduce levels of the virus in the bloodstream of people who became infected. 

 

Eli Lilly on Friday announced that it has received FDA approval for its bone-strengthening drug raloxifene, sold under the brand-name Evista, to reduce the risk of breast cancer for postmenopausal women at high risk of the disease and postmenopausal women with osteoporosis, the Wall Street Journal reports (Wall Street Journal, 9/15).

参考翻译（suggested translation）
据Wall Street Journal报道，Eli Lily在周五宣称它的骨质强化药物raloxifene，商品名为Evista，已经取得了FDA的认证，这种药物可以降低具有高危因素的绝经妇女乳腺癌的风险，以及绝经妇女患骨质疏松的风险。

FDA in 1997 approved Evista to help prevent osteoporosis and in 1999 approved it to treat the disease. Tamoxifen, which blocks the production of estrogen, is the only other FDA-approved drug for reducing breast cancer risk, but it increases risk for uterine cancer and blood clots. Raloxifene, which also blocks estrogen production, has been shown to be as effective as tamoxifen at reducing breast cancer risk, though it increases risk of hot flashes and other menopause-related symptoms.

 

In documents released in July, FDA said Evista lowers the risk of invasive breast cancer in some patients. The drug also proved effective in reducing the risk of breast cancer in postmenopausal women whose cancer is fueled by estrogen; however, there seemed to be no decrease in risk among patients whose cancer did not need estrogen to grow, FDA reviewers said in the documents. They also said that studies have provided less evidence for using the drug to reduce the risk of developing invasive breast cancer in postmenopausal women at high risk of developing the disease (Kaiser Daily Women's Health Policy Report, 7/25).

 

参考翻译（suggested translation）
评论家在FDA七月发布的文件中说，FDA称Evista能够降低某些患者乳腺癌的浸润生长风险。该药被证实能够有效降低绝经妇女的雌激素依赖性乳腺癌的风险，而对非雌激素依赖性乳腺癌的患者则无效。通时评论家还提到没有证据显示这种药物可以降低有乳腺癌高危因素的绝经妇女的浸润生长的风险。

In its approval announcement Friday, FDA noted that Evista can cause blood clots in the legs, leg cramps, swelling of the legs and feet, hot flashes, flu-like symptoms, joint pain, sweating and an increased risk of death due to stroke. FDA said that women with current or prior blood clots in the legs, lungs or eyes should not use Evista, adding that premenopausal women and women who are or might become pregnant should not take the drug. Evista should not be taken with cholestyramine, a drug used to lower cholesterol levels, or estrogens, the agency said (Fahy, Pittsburgh Post-Gazette, 9/15). According to the Journal, the drug will carry a boxed warning saying that a study found that although Evista users did not have a higher incidence of stroke, users who had had a stroke had a higher mortality rate (Wall Street Journal, 9/15).

 

正式离开普外到了肝胆科，主任没有给排夜班，前段在时间在普外经常半夜急诊手术，白天择期手术有些失代偿了，终于有时间可以好生修整一下，能够按时睡觉，感觉真好。

 才到肝胆科就被普外主任又叫回了科室继续上班，昨天值班，晚上来了个阑尾炎，冉老师没有上台，我和李医生直接搞定，感觉比1月多前到外科时候熟练多了，虽然手术下来已经是凌晨2点有点累，但真是十分欣喜！加油！年轻无极限！

今天转到了肝胆外科，早上主任居然亲自教我系腹带，好感动.

 

晚上回来自己在家练习了好阵，终于比较熟悉了。

                  告别城市的喧嚣，呼吸下山野的清新空气让人惬意万分。
                                     烟雨蒙蒙的大梁山